The Regulatory Boundary: Medicines versus Cosmetics - Navigating Act 101 and SAHPRA Compliance in South Africa
The High Cost of Unintentional Medicinal Status
Imagine scaling a dermo-cosmetic formulation from the laboratory bench to a commercial batch of 20,000 units. Packaging is printed, secondary cartons are embossed, distribution agreements with national retail pharmacies are executed, and stock is staged in the warehouse. Two weeks before national distribution, an enforcement notice arrives from the South African Health Products Regulatory Authority (SAHPRA).
The grounds: your front-of-pack claims declare that your proprietary peptide serum "reverses cellular senescence and treats chronic dermal micro-inflammation."
Under South African law, that single phrasing transforms your cosmetic into an unapproved, unregistered medicine. The operational fallout is immediate and severe:
Consignments are embargoed or seized under statutory powers.
Retail accounts freeze your vendor listing and cancel purchase orders.
Capital deployed into primary and secondary packaging is written off entirely.
Brand founders and corporate directors face potential criminal liability and financial penalties under national legislation.
This scenario occurs regularly across South Africa’s personal care and aesthetic medicine sectors. Clinicians, scientists, and brand owners often understand the cellular pharmacology of their active ingredients intimately, yet remain blind to how statutory definitions dictate commercial viability.
1. The Dangerous Grey Area Between Beauty and Medicine
1.1 Defining Cosmetic Function: Altering Appearance vs. Treating Pathology
The functional boundary between a medicine and a cosmetic rests on product intent and target tissue pathology:
Cosmetic Function: Under Act 54 of 1972, a cosmetic acts externally on the epidermis, hair system, nails, lips, and external genital organs. Its statutory purpose is confined to cleansing, perfuming, modifying appearance, protecting, or maintaining these structures in good condition. A cosmetic improves how healthy or aged tissue looks; it does not cure underlying diseased tissue.
Medicinal Function: Under Act 101 of 1965, a medicine targets etiology, structural modification, and pathological resolution. If a formulation aims to alter physiological processes—such as down-regulating inflammatory cytokines in atopic flares, up-regulating fibroblastic procollagen synthesis at an organic level, or eradicating pathogenic colonies of Cutibacterium acnes—it is operating as a medicine.
Aesthetic professionals transitioning to formulation often fall into a clinical habit: describing biological mechanisms of action on commercial packaging. When marketing to the end consumer, detailing cellular biochemical cascades creates immediate regulatory liability.
1.2 The Regulatory Cost of Accidental Medicinal Status Under Act 101
Classifying a product as an unregistered medicine under Act 101 triggers statutory interventions:
Section 14 Prohibition: It is a direct criminal offense to sell any medicine that is subject to registration under Section 14 of Act 101 if that medicine has not been registered by SAHPRA.
Commercial Embargo and Seizure: Section 28 empowers SAHPRA-appointed inspectors to enter manufacturing sites, logistics hubs, or retail distribution centers to impound, seize, and seal non-compliant inventory.
Retail De-Listing: Major pharmacy chains and retail groups immediately quarantine stock upon receiving regulatory queries or complaints filed with the Advertising Regulatory Board (ARB) or SAHPRA.
Reputational and Financial Loss: Beyond the loss of packaging inventory, reformulating, relabeling, and rebuilding distribution pipelines can stall a brand's commercial momentum for 12 to 24 months.
2. Decoding Act 101 of 1965 for Formulators
2.1 The Statutory Definition of a Medicine and Therapeutic Effect
Section 1 of the Medicines and Related Substances Act 101 of 1965 defines a medicine as:
"Any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in—(a) the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state or the symptoms thereof in human beings; or(b) restoring, correcting or modifying any somatic or psychic or organic function in human beings."
A critical element in this statutory text is the phrase: "purporting to be suitable for use."
Under South African legal precedent, a product does not need to possess confirmed clinical efficacy to be classified as a medicine under Act 101. If your label, social media channels, or patient collateral claims or implies that the preparation treats, prevents, or modifies a condition or abnormal state, the product may be legally categorized as a medicine by virtue of its purported effect.
2.2 Why Disease-Curing Claims Trigger Mandatory SAHPRA Registration
The presence of disease-curing, disease-mitigating, or physiological claims strips a product of its cosmetic status and subjects it to SAHPRA’s registration framework:
Metric | Cosmetic Path (FCD Act 54) | Pharmaceutical Path (MRS Act 101) |
Regulatory Gate | Self-compliance, Safety Assessment (CPSR), GMP | Pre-market CTD Dossier Submission to SAHPRA |
Time-to-Market | Months (upon safety clearance) | Multiple years (technical evaluation queue) |
Manufacturing Requirement | ISO 22716 / SANS 22716 Cosmetic GMP | PIC/S-aligned Pharmaceutical GMP License |
Claim Substantiation | ARB / Consumer Protection compliance | Randomized clinical trials, Phase I–III dossiers |
Claiming to "cure acne," "heal eczema," or "mitigate alopecia" places the product under Section 14 evaluation. Unless an applicant has compiled a full Common Technical Document (CTD) dossier and received a registration certificate from SAHPRA, distribution is illegal.
2.3 Boundary Ingredients: When a Raw Material Borders on a Scheduled Substance
Formulators frequently work with compounds that exist on the boundary between cosmetic ingredients and scheduled pharmaceutical substances. Understanding the chemical threshold and statutory schedule under Act 101 is essential:
Compound Class | Cosmetic Status (Act 54 of 1972) | Medicinal Status (Act 101 of 1965) |
Retinoids | Retinol, Retinyl Palmitate, Hydroxypinacolone Retinoate (within toxicologically verified thresholds) | Retinoic Acid (Tretinoin), Isotretinoin, Adapalene (Schedule 3 / 4; Prescription Only) |
Depigmenting Agents | Alpha-Arbutin, Niacinamide, Kojic Acid, Azelaic Acid (<10%) | Hydroquinone (Banned in cosmetics; Scheduled active requiring a physician's prescription) |
Hydroxy Acids | Glycolic, Lactic, and Salicylic Acid (Low concentrations for superficial stratum corneum exfoliation) | High-concentration clinical peel solutions formulated for medical dermal ablation |
Cannabinoids | Low-dose isolated CBD (<20 mg daily pack threshold; strictly zero therapeutic claims) | High-dose CBD or any synthetic/THC-dominant formulations (Schedule 4 or Schedule 6) |
Formulators cannot simply select an ingredient from a raw material distributor's catalogue without evaluating its status against the latest Schedules published under the MRS Act.
3. Copywriting and Marketing Hazards
3.1 Prohibited Words: The Clinical Lexicon That Triggers Enforcement
Clinical practitioners often default to therapeutic terminology when describing product efficacy. In cosmetic commercialisation, using this vocabulary on packaging or digital collateral creates immediate legal exposure:
❌ "Cure" or "Heal": Implies the reversal of underlying pathology. Legally restricted to therapeutic interventions.
❌ "Treats": Directly triggers the statutory definition under Section 1(a) of Act 101 ("treatment, mitigation... of disease").
❌ "Anti-inflammatory": Inflammation is a complex somatic and vascular response. Claiming to suppress it designates the product as an unregistered anti-inflammatory medicine.
❌ "Antibacterial / Antiseptic against acne": Explicitly purports to eradicate C. acnes, crossing from cosmetic maintenance into antimicrobial therapy.
❌ "Cellular Regeneration" / "Stimulates DNA Repair": Crosses the threshold into structural and somatic modification under Section 1(b) of Act 101.
4. Compliance Audit Protocol
4.1 Cross-Verifying Front-of-Pack Claims Against Product Intent
Before approving print-ready packaging artwork, the regulatory lead, formulating chemist, and brand owner must conduct an exhaustive cross-verification audit:
Primary Face Panel Audit: Verify that the product identity is unequivocally cosmetic. Ensure the total absence of trigger words such as treat, heal, cure, or remedy.
Secondary & Side Panel Audit: Audit directions for use and technical descriptions. Verify that descriptive copy explains surface appearance alteration rather than internal cellular modification.
Digital & Promotional Collateral Audit: Review e-commerce meta-descriptions, digital ad copy, brand blogs, and social media captions. In South Africa, promotional marketing material is treated by enforcement authorities as an extension of the product's packaging claims.
4.2 Documenting Self-Assessment Files for SAHPRA Exemption Confirmation
Under South African cosmetic governance, there is no formal certificate issued by the Department of Health that reads "Approved as a Cosmetic." Exemption from Act 101 operates on a self-regulatory compliance framework backed by scientific and legal documentation.
To confirm exemption and defend against competitor complaints or regulatory inquiries, the brand owner must assemble an internal SAHPRA Exemption Dossier as part of the master Product Information File (PIF):
Intended Use Rationale: A signed scientific brief establishing that the product's primary objective is to alter, cleanse, or beautify appearance.
Quantitative Toxicological Clearance: A completed Cosmetic Product Safety Report (CPSR) demonstrating that raw materials operate at non-systemic, safe cosmetic inclusion levels.
Absence of Scheduled Substances Declaration: Explicit verification that no component is listed in Schedules 1 through 6 of Act 101 of 1965.
Claim Substantiation Dossier: Independent, empirical evidence (such as panel studies or consumer trials) supporting all marketing statements, aligned with the Advertising Regulatory Board (ARB) Code of Advertising Practice.
Book a meeting with the Innoeco Business Team to discuss your compliance status and get a free compliance audit.
Comments